About the Authors
- Brendan L. Limone
-
Affiliations Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, Connecticut, United States of America, Department of Pharmacy, Hartford Hospital, Hartford, Connecticut, United States of America
- William L. Baker
-
Affiliation Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, Connecticut, United States of America
- Jeffrey Kluger
-
Affiliation Department of Cardiology, Hartford Hospital, Hartford, Connecticut, United States of America
- Craig I. Coleman
-
* E-mail: ccolema@harthosp.org
Affiliations Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, Connecticut, United States of America, Department of Pharmacy, Hartford Hospital, Hartford, Connecticut, United States of America
Competing Interests
This study received funding from Janssen Pharmaceuticals. Dr. Coleman is a member of the Janssen Pharmaceuticals advisory board and speaker’s bureau for Xarelto®. Rivaroxaban is a Janssen Pharmaceuticals product. There are no further patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: BLL WLB CIC. Performed the experiments: BLL WLB CIC. Analyzed the data: BLL WLB JK CIC. Contributed reagents/materials/analysis tools: BLL WLB JK CIC. Wrote the paper: BLL WLB JK CIC.